GlaxoSmithKline (GSK) says it will close its main research and development hub in Stevenage as part of a broader restructuring that includes opening a new site in Cambridge. Multiple outlets report that the change affects roughly 1,800 staff currently based in Stevenage. The company links the relocation to strengthening its medicines pipeline and to concentrating activities within the UK’s life sciences cluster around Cambridge. The BBC reports that around 1,000 staff are expected to be placed at the new Cambridge location, describing it as being at the “heart” of the UK’s life sciences “Golden Triangle.” The Financial Times adds that GSK is also announcing a major cost-saving drive, with the restructuring described in connection with planned savings and operational changes totaling £1.9bn. While the reports focus on workforce impacts and the shift of R&D activity to Cambridge, they also present the move as part of GSK’s strategy to align research capabilities with future growth areas.